Skip to main content

Table 2 Adjusted hazard ratios and 95% confidence intervals of BMI and CMD for mortality in breast and colorectal cancer patients by stage at diagnosis

From: Impact of cumulative body mass index and cardiometabolic diseases on survival among patients with colorectal and breast cancer: a multi-centre cohort study

  

BMI (continuous, per 1 kg/m2)

CMD (reference: no CMD)

 

n

Adjusted for CMD

HR (95%-CI)

P-value (LR test)

Adjusted for BMI

HR (95%-CI)

p-value (LR test)

Colorectal cancer

All stages

1045

No

1.06 (1.02–1.10)*

 

No

1.25 (0.97–1.61)

 
  

Yes

1.06 (1.02–1.09)*

0.065

Yes

1.22 (0.94–1.57)

0.002*

Localised

532

No

1.10 (1.04–1.17)*

 

No

1.73 (1.15–2.59)*

 
  

Yes

1.11 (1.04–1.18)*

0.031*

Yes

1.76 (1.17–2.66)*

0.002*

Advanced

513

No

1.03 (0.99–1.08)

 

No

1.17 (0.83–1.64)

 
  

Yes

1.03 (0.98–1.07)

0.683

Yes

1.12 (0.80–1.59)

0.213

Breast cancer

All stages

1620

No

1.04 (1.00–1.08)*

 

No

1.46 (1.01–2.09)*

 
  

Yes

1.04 (1.00–1.08)*

0.069

Yes

1.42 (0.99–2.05)

0.135

Localised

1032

No

1.07 (1.01–1.13)*

 

No

1.38 (0.78–2.46)

 
  

Yes

1.07 (1.01–1.13)*

0.371

Yes

1.31 (0.74–2.35)

0.009*

Advanced

588

No

1.01 (0.96–1.07)

 

No

1.51 (0.95–2.42)

 
  

Yes

1.01 (0.96–1.07)

0.103

Yes

1.51 (0.94–2.41)

0.513

  1. Cox proportional regression stratified by sex (for colorectal cancer), age and country and adjusted for smoking, physical activity, alcohol consumption and education
  2. BMI: Predicted mean body mass index between age 20 and 50, continuous
  3. CMD: Diagnosis of cardiometabolic diseases including myocardial infraction, stroke or type 2 diabetes
  4. P-values of likelihood ratio tests (LR test) comparing models that include CMD in addition to BMI with models including only BMI / comparing models that include BMI in addition to CMD with models including only CMD
  5. *Statistically significant on a significance-level of p <  = 0.05